RELAPSING MULTIPLE SCLEROSIS

This Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…

This Phase 3 trial tests whether the oral drug remibrutinib works better than teriflunomide at reducing relapses and slowing disability in people with relapsing multiple sclerosis. About 1,000 adults aged 18–55 with active MS are taking part. The study is double-blind, meaning ne…

This phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…

This study looks at whether a one-year treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard treatments. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups. Their walking abi…

This study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…

This phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to se…

This Phase 3 trial tests remibrutinib, an oral tablet, against teriflunomide in 1000 adults with relapsing multiple sclerosis. The goal is to see if remibrutinib better reduces yearly relapse rates and delays disability. Participants will then have the option to continue remibrut…

This study follows about 1,900 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Participants continue receiving ofatumumab injections every 4 weeks to monitor long-term safety, side effects, and how well the drug controls re…

This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…

This study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…

This study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…

This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.

This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch imp…

This Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …

This study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…

This study is testing whether the drug ocrelizumab (Ocrevus) can improve signs of inflammation in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first attack (clinically isolated syndrome). Thirty participants will receive ocreliz…

This program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is designed for people who have no other treatment options. The goal is to provide the drug while researchers continue to study its safety and effectivenes…

This study tests whether obexelimab can safely reduce brain lesions in people with relapsing multiple sclerosis (MS). About 93 adults with active relapses or recent MRI lesions will receive either the drug or a placebo. The main goal is to count new brain lesions on MRI scans ove…

This Phase 2 trial tests a drug called SAR441344, which blocks a protein (CD40L) involved in immune attacks. The goal is to see if it can reduce new active brain lesions in people with relapsing multiple sclerosis. About 129 adults aged 18-55 with relapsing MS are participating, …

This study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…

This study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to…

This observational study follows 367 adults with relapsing multiple sclerosis who are taking cladribine tablets (Mavenclad) in routine care. Researchers want to find out which patient characteristics predict how long people stay on the drug and how well it works. The goal is to h…

This study observes 106 Austrian patients with relapsing multiple sclerosis who are already taking Ofatumumab (Kesimpta). Researchers compare those who started the drug early versus later, tracking disease activity over two years. The goal is to see if early treatment leads to fe…